Ulcerative colitis

June 26, 2015June 26, 2015

Immune Pharmaceuticals Initiates Phase II Studies of Bertilimumab for Ulcerative Colitis and Bullous Pemphigoid

News, Ulcerative colitis

Immune Pharmaceuticals Inc., a company currently developing novel, highly-targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer, recently announced the initiation of a Phase II Ulcerative ... Read more

June 24, 2015June 24, 2015

New Study Reveals Safe, Effective Therapy for Active Ulcerative Colitis

News, Ulcerative colitis

A new study conducted by an international research team recently revealed that the corticosteroid, beclomethasone dipropionate (BDP), can be successfully employed as a treatment strategy for patients with active mild-to-moderate ... Read more

June 19, 2015June 19, 2015

Galapagos Finishes Enrollment of Patients with Ulcerative Colitis for IBD Trial

News, Ulcerative colitis

Galapagos NV recently announced that the company has completed recruitment of patients with ulcerative colitis for its phase 2 proof-of-concept study designed to evaluate GLPG1205 as a possible therapy for inflammatory bowel diseases (IBD). Galapagos ... Read more

June 9, 2015June 10, 2015

Study Finds Specific T Cells Involved in Persistent Inflammatory Response in Ulcerative Colitis

News, Ulcerative colitis

In a recent study published in the International Journal of Clinical and Experimental Pathology, a team of researchers found that specific T cells may act as major effector cell subsets in ... Read more

May 5, 2015May 18, 2015

New Set Of Guidelines Released, Critiqued For Non-Hospitalized Patients With Ulcerative Colitis

News, Ulcerative colitis

A group of Canadian experts recently published a set of guidelines aimed at improving treatment of Ulcerative Colitis (UC) for patients who are not hospitalized and are affected by mild to severe forms of the ... Read more

April 22, 2015September 28, 2016

Receptos Announces Positive Results for Ulcerative Colitis Therapy in Maintenance Period of Phase 2 Trial

Ulcerative colitis

Receptos, Inc. a biopharmaceutical company that develops drug candidates for the treatment of immune and metabolic diseases, recently announced positive results for the maintenance period of TOUCHSTONE, a Phase 2 clinical ... Read more

April 13, 2015April 13, 2015

Fecal Immunochemical Test Found to Be an Accurate Predictor of Mucosal Status in Ulcerative Colitis Patients

News, Ulcerative colitis

Researchers at the Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences and Wakayama Medical University in Japan recently revealed that two assays, fecal immunochemical test (FIT) and fecal calprotectin ... Read more

April 7, 2015September 12, 2016

New Home Test Kit Launched for Crohn’s and Ulcerative Colitis

Colon Cancer, News, Ulcerative colitis

Germany-based Bühlmann Laboratories has launched IBDoc, described as “the first in-vitro diagnostic test to measure the fecal inflammation marker calprotectin at home.” The announcement marks the continuing advancement toward personalized medicine. ... Read more

March 20, 2015March 20, 2015

Teen With IBD Conquers 13.1 Mile Marathon For Crohn’s Disease And Ulcerative Colitis

News, Ulcerative colitis

Chayla is a beautiful 16 year old girl. Although she is missing her hair and might look like she is going through cancer chemotherapy, she is not. She is one of ... Read more

March 19, 2015March 19, 2015

Samsung Submits MAA for Remicade Biosimilar For Crohn’s Disease, Ulcerative Colitis to EMA

Crohn's Disease, News, Ulcerative colitis

Samsung Bioepis Co. Ltd. recently submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) regarding a biosimilar treatment for several conditions, including Crohn’s disease and ulcerative colitis. The Remicade (Infliximab) ... Read more